Graybug to Present at the 2022 OIS Retina Innovation Summit
July 06, 2022 07:15 ET
|
Graybug Vision, Inc.
BALTIMORE, July 06, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug Announces Review of Strategic Alternatives
June 28, 2022 07:15 ET
|
Graybug Vision, Inc.
BALTIMORE, June 28, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug to Present Clinical Development Plan Update for GB-102 at the 2022 Clinical Trials at the Summit Meeting
May 19, 2022 07:30 ET
|
Graybug Vision, Inc.
BALTIMORE, May 19, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular...
Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual Meeting
April 27, 2022 07:30 ET
|
Graybug Vision, Inc.
BALTIMORE, April 27, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug to Present at the 2022 ASCRS Annual Meeting
April 18, 2022 07:30 ET
|
Graybug Vision, Inc.
BALTIMORE, April 18, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...